Research institution
H. Lee Moffitt Cancer Center and Research Institute Clinical Trials
Studies where H. Lee Moffitt Cancer Center and Research Institute is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 74Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Digoxin Medulloblastoma Study
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
- Trial name
- NCT06701812
- Testing
- Digoxin
- Where
- 18 sites in United States
- Volunteers
- 23 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
- Trial name
- NCT06963346
- Testing
- Romidepsin, Durvalumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastases, HR+ Metastatic Breast Cancer
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
- Trial name
- NCT04923542
- Testing
- Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Follicular Lymphoma, Marginal Zone Lymphoma
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
- Trial name
- NCT06350318
- Testing
- Zanubrutinib, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Ewing Sarcoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES).
- Trial name
- METTSEO (NCT07194044)
- Testing
- Vincristine, Doxorubicin, Cyclophosphamide
- Where
- 21 sites in United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
- Trial name
- NCT06144606
- Testing
- Tecartus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Triple Negative Breast Cancer
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
- Trial name
- NCT05528133
- Testing
- Genomically Guided Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Mantle Cell Lymphoma
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with…
- Trial name
- NCT06553872
- Testing
- Pirtobrutinib, Brexucabtagene Autoleucel
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Oropharyngeal Cancer, HPV-Related Carcinoma
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100…
- Trial name
- BASH OPC (NCT06305676)
- Testing
- combined HPV 16 DNA and host gene methylation oral biomarker panel
- Where
- 3 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age…
- Trial name
- NCT06745882
- Testing
- Cisplatin, Carboplatin, Pemetrexed
- Where
- 11 sites in United States
- Volunteers
- 318 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Completed, with results posted
All 132Smoking Cessation
Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers
This study evaluates the efficacy and economic impact of a theoretically-based, fully automated, interactive smartphone-based smoking cessation intervention.
- Trial name
- NCT05004662
- Testing
- Smartphone-delivered automated treatment, Nicotine patch, Counseling
- Where
- United States
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.
- Trial name
- NCT04151667
- Testing
- Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Kidney Cancer
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
The main purpose of this study is to evaluate the effects of the interleukin-2 given in combination with pembrolizumab. Interleukin-2 (IL-2) is also called aldesleukin, or Proleukin™.
- Trial name
- NCT02964078
- Testing
- Pembrolizumab, Interleukin-2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
This is a Phase 2 open-label, single-arm study of neoadjuvant treatment of intratumoral tavo-EP plus nivolumab IV infusion. Eligible participants will be those with pathological diagnosis of operable locally-regionally advanced…
- Trial name
- NCT04526730
- Testing
- Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Surgical Wound Infection
NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies
This randomized trial will use a Negative Pressure Wound Therapy device or standard wound closure, in participants with gastrointestinal neoplasms, to measure the rate of surgical site infections
- Trial name
- NCT04955730
- Testing
- Negative Pressure Wound Therapy
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute